Related Experiment Video
Updated: May 7, 2026

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Are MPNs vascular diseases?
Guido Finazzi1, Valerio De Stefano, Tiziano Barbui
1Division of Hematology, Ospedale Papa Giovanni XXIII, Piazza OMS, 1, 24127, Bergamo, BG, Italy, gfinazzi@hpg23.it.
Abstract:
A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence of venous thrombosis in atypical sites, such as the splanchnic district, and the involvement of plasmatic prothrombotic factors, including an acquired resistance to activated protein C, both link MPN to inherited thrombophilia. Anticoagulants are the drugs of choice for these complications. The pathogenic role of leukocytes and inflammation, and the high mortality rate from arterial occlusions are common features of MPN and atherosclerosis. The efficacy and safety of aspirin in reducing deaths and major thrombosis in PV have been demonstrated in a randomized clinical trial. Finally, the Virchow's triad of impaired blood cells, endothelium and blood flow is shared both by MPN and thrombosis in solid cancer. Phlebotomy and myelosuppressive agents are the current therapeutic options for correcting these abnormalities and reducing thrombosis in this special vascular disease represented by MPN.
Insights
Myeloproliferative neoplasms (MPNs) like polycythemia vera (PV) and essential thrombocythemia (ET) significantly increase thrombosis risk. Management involves anticoagulants, aspirin, phlebotomy, and myelosuppressive agents to reduce vascular complications.
Area of Science:
- Hematology
- Oncology
- Vascular Medicine
Background:
- Chronic myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) and essential thrombocythemia (ET), are characterized by a high risk of arterial and venous thrombosis.
- Thrombosis in MPNs shares clinical and pathogenetic features with other vascular diseases, including inherited thrombophilias and atherosclerosis.
Purpose of the Study:
- To review the clinical aspects, pathogenesis, and management of thrombosis in MPNs.
- To highlight the commonalities between MPN-associated thrombosis and other vascular pathologies.
- To discuss current therapeutic strategies for reducing thrombosis in MPNs.
Main Methods:
- Literature review and synthesis of existing research on MPN-associated thrombosis.
- Comparison of MPN thrombosis with inherited thrombophilias, atherosclerosis, and thrombosis in solid cancers.
- Analysis of therapeutic options including anticoagulants, aspirin, phlebotomy, and myelosuppressive agents.
Main Results:
- MPN-associated thrombosis involves atypical venous sites and acquired resistance to activated protein C, linking it to inherited thrombophilia.
- Leukocyte and inflammation roles, along with high mortality from arterial occlusions, connect MPNs to atherosclerosis.
- Aspirin has proven efficacy in reducing thrombosis and mortality in PV.
- Virchow's triad (impaired blood cells, endothelium, blood flow) is relevant to both MPNs and thrombosis in cancer.
Conclusions:
- Anticoagulants are primary for managing thrombotic complications in MPNs.
- Aspirin is effective for reducing thrombosis and mortality in PV.
- Phlebotomy and myelosuppressive agents are key therapies for correcting underlying abnormalities and preventing thrombosis in MPNs.
Related Concept Videos
Mitral Stenosis I: Introduction
Mitral Valve Prolapse III: Nursing Management
Peripheral Artery Disease IV: Nursing Management
Mitral Stenosis IV: Nursing Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Cardiomyopathy I: Introduction and Classification
